PROVIDENCE, R.I. (WPRI) — As one of the most common chronic conditions, asthma affects millions of children worldwide. More than 26 million Americans are living with the condition, and about 7 million ...

A severe asthma attack is not just an escalation of breathlessness, it is a medical emergency that can spiral into respiratory failure within minutes if ignored. With airways suddenly narrowing, ...

Children’s Health Ireland (CHI) has issued a ‘sincere apology’ for shortcomings in the care of a Dublin teenager who died following a severe asthma attack while waiting over four years to see a ...

What Is Exdensur, and Why Does It Matter? Exdensur (depemokimab) is a new type of ultra long-acting biologic medicine approved by the FDA as an add-on maintenance treatment for severe eosinophilic ...

A new option for hard-to-control asthma: The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma. Designed to reduce flare-ups: The injectable ...

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced. The ...

People with severe asthma sometimes rely on daily steroid pills, which raise the risk of diabetes, infections and bone problems. Now, a study supports the idea that a monthly antibody injection is a ...

Monthly injection with tezepelumab helped 90% of patients with severe asthma reduce intake of daily steroid tablets. The corresponding study was published in The Lancet Respiratory Medicine. “In this ...

Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype Approval based on SWIFT trials showing ...